Reflections on betalactam antibiotics administered by continuous infusion;Algunas reflexiones acerca de la administración de antibióticos betalactámicos en infusión continua

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 24, Issue 7, 2006, Pages 445-452

  López, Ester ^a   Soy, Dolors ^a   Miana, Ma Teresa ^a   Codina, Carles ^a   Ribas, Josep ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Betalactam antibiotics; Continuous infusion; Pharmacodynamics; Pharmacokinetics

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFTAZIDIME; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBIOTIC THERAPY; CONTINUOUS INFUSION; DRUG EFFICACY; FEBRILE NEUTROPENIA; FIBROSIS; HOSPITAL INFECTION; HUMAN; LUNG INFECTION; MINIMUM INHIBITORY CONCENTRATION; REVIEW;

EID: 33749406418     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13091783     Document Type: Review

References (50)

1. American Thoracic Society/European Respiratory Society Statement. Guidelines for the management of adults with hospital-acquired ventilator-associated and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388-416.
2. Turnidge JD. The pharmacodynamics of β-lactams. Clin Infect Dis. 1998;27:10-22.
3. Mehrotra R, De Gaudio R, Palazzo M. Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. Intensive Care Med. 2004;30:2145-56.
4. Craig WA. Antibiotic selection factors and description of a hospital-based outpatient antibiotic therapy program in the USA. Eur J Clin Microbiol Infect Dis. 1995;14:636-42.
5. Vogelman B, Craig WA. Kinetics of antimicrobial activity. J Pediatr. 1986;108:865-40.
6. Mouton JW, Vinks AA. Is continuous infusion of beta-lactam antibiotics worthwhile? - Efficacy and pharmacokinetic considerations. J Antimicrob Chemother. 1996;38:5-15.
7. Bundtzen RW, Gerber AU, Cohn DL, Craig WA. Postantibiotic suppression of bacterial growth. Rev Infect Dis. 1989;159:281-92.
8. Jacobs MR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect. 2001;7:589-96.
9. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis. 1995;22:89-96.
10. Ariano RE, Nyhlén A, Donnelly JP, Sitar DS, Harding GK, Zelenitsky SA. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother. 2005;39:32-8.
11. Mouton JW, Hollander JG. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother. 1994;38:931-6.
12. Cappelletty DM, Kang SL, Palmer SM, Rybak JM. Pharmacodynamics of ceftazidime administered as continuous infusion or intermitent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model. Antimicrob Agents Chemother. 1995;33:1797-801.
13. Alou L, Aguilar L, Sevillano D, Giménez MJ, Echeverría O, Gómez-Lus ML, et al. Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model. J Antimicrob Chemother. 2005;55:209-13.
14. Nicolau DP, Nightingale CH, Banevicius MA, Fu Q, Quintiliani R. Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections. Antimicrob Agents Chemother. 1996;40:61-4.
15. Benko AS, Cappelletty DM, Kruse JA, Rybak MJ. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected Gram-negative infections. Antimicrob Agents Chemother. 1996;40:691-5.
16. Lipman J, Gomersall CD, Gin T, Joynt GM, Young RJ, Continuous infusion ceftazidime in intensive care: a randomized controlled trial. J Antimicrob Chemothe. 1999;43:309-11.
17. Cousson J, Floch T, Vernet-Garnier V, Appriou M, Petit JS, Jovenin N, et al. Pharmacodynamic interest of ceftazidime continuous infusion vs intermittent bolus administration in patients with severe nosocomial pneumonia. Pathol Biol (Paris). 2005;53:546-50.
18. Boselli E, Breilh D, Rimmelé T, Poupelin JC, Saux MC, Chassard D, et al. Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Intensive Care Med. 2004;30:989-91.
19. Burgess DS, Waldrep T. Pharmacokinetics and pharmacodymamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing. Clin Ther. 2002;24:1090-104.
20. Buck C, Bertram N, Ackermann T, Sauerbruch T, Derendorf H, Paar WD. Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion. Int J Antimicrob Agents. 2005;25:62-7.
21. Burgess DS, Hastings RW, Hardin TC. Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion. Clin Ther. 2000;22:66-75.
22. Drusano GL. Prevention of resistance: a goal for dose selection of antimicrobial agents. Clin Infect Dis. 2003;36 Suppl 1:42-50.
23. Dandekar PK, Maglio D, Sutherland CA, Nightingale CH, Nicolau DP. Pharmacokinetics of Meropenem 0.5 and 2 g Every 8 Hours as a 3-Hour Infusion. Pharmacotherapy. 2003;23:988-91.
24. Jaruratanasirikul S, Sriwiriyajan S. Comparison of the pharmacodynanlics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection. J Antimicrob Chemother. 2003;52:518-21.
25. Thalhammer F, Traunmüller F, El Menyawi I, Frass M, Hollenstein UM, Locker GJ, et al. Continuous infusion versus intermittent administration of meropenem in critically ill patients. J Antimicrob Chemother. 1999;43:523-7.
26. Boselli E, Breihl D, Duflo F, Saux MC, Debon R, Chassard D, et al. Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia. Crit Care Med. 2003;31:2102-6.
27. Boselli E, Allaouchiche B. Diffusion pulmonaire des antibiotiques. Analyse critique de la littérature. Ann Fr Anesth Reanim. 2001;20:612-30.
28. Baldwin DR, Maxwell SR, Honeybourne D, Andrews, JM, Ashby JP, Wisc R, et al. Penetration of cefpirome into the potential sites of pulmonary infection. J Antimicrob Chemother. 1991;28:79-86.
29. Kuti JL, Nightingale CH, Quintiliani R, Nicolau DP. Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis. Diagn Microbiol Infect Dis. 2002;44:51-7.
30. Reese MA, Frei CR, Burgess DS. Pharmacodynamics of intermittent and continuous infusion piperacillin/tazibactam and cefepime against extended-spectrum β-lactamase-producing organisms. Int J Antimicrob Agents. 2005;26:114-9.
31. Frei CR, Burgess DS. Continuous infusion β-lactams for intensive care unit pulmonary infections. Clin Microbiol Infect. 2005;11:418-21.
32. Tam VH, Louie A, Lomaestro BM, Drusano GL. Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa. Pharmacotherapy. 2003;23:291-5.
33. Krueger WA, Burlitta J, Kinzing-Shippers M, Landersdorfer C, Holzgrabe U, Naber KG, et al. Evaluation by Monte Carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittenly or as a continuous infusion in healthy volunteers. Antimicrob Agents Chemother. 2005;49:1881-9.
34. Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol. 2003;43:1116-23.
35. Nicolau DP, McNabb J, Lacy MK, Quintiliani R, Nightingale CH. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents. 2001;17:497-504.
36. McNabb J, Nightingale CH, Quintiliani R, Nicolau DP. Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia. Pharmacotherapy. 2001;21:549-55.
37. Hanes SD, Wood GC, Herring V, Croce MA, Fabian TC, Pritchard E, et al. Intermittent and continuous ceftazidime infusion for critically ill trauma patients. Am J Surg. 2000;179:436-40.
38. Grant EM, Kuti JL, Nicolau DP, Nightingale CH, Quintiliani R. Clinical efficacy and pharmacoeconomics of a continuous infusion piperacillin-tazobactam program in a large community teaching hospital. Pharmacotherapy. 2002;22:471-83.
39. Egerer G, Goldscmidt H, Hensel M, Harter C, Schneeweiss A, Ehrhard I, et al. Continuous infusion of ceftazidime for patients with breast cancer and multiple myeloma receiving high-dose chemotherapy and peripheral blood stem cell transplantation. Bone Marrow Transplant. 2002;30:427-31.
40. Marshall E, Smith DB, O'Reilly SM, Murray A, Kelly V, Clark PI. Low-dose continuous-infusion ceftazidime monotherapy in low-risk febrile meutropenic patients. Support Care Cancer. 2000;8:198-202.
41. Daenen S, Erjavec Z, Uges DR, De Vries-Hospers HG, De Jonge P, Halie MR. Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia. Eur J Clin Microbiol Infect Dis. 1995;14:188-92.
42. Nyhlen A, Ljungberg B, Nilsson-Ehle I. Pharmacokinetics of ceftazidime in febrile neutropenic patients. Scand J Infect Dis. 2001;33:222-6.
43. Pea F, Viale P, Damiani D, Pavan F, Cristini F, Fanin R, et al. Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure. Antimicrob Agents Chemother. 2005;49:3550-3.
44. Vinks AT, Brimicombe RW, Heijerman HG, Bakker W. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics. J Antimicrob Chemother. 1997;40:125-33.
45. Rappaz I, Decosterd LA, Bille J, Pilet M, Bélaz N, Roulet M. Continuous infusion of ceftazidime with a portable pump is as effective as a thrice-a-day bolus in cystic fibrosis children. Eur J Pediatr. 2000;159:919-25.
46. Kuti JL, Nightingale CH, Knauft RF, Nicolau DP. Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis. Clin Ther. 2004;26:493-501.
47. Mohr JF, Wagner A, Rex JH. Pharmacokinetic/pharmacodynamic modeling can help guide targeted antimicrobial therapy for noscomial Gram-negative infections in critically ill patients. Diagn Microbiol Infect Dis. 2004;48:125-30.
48. Viaene E, Chanteaux H, Servais H, Mingeot-Leclercq MP, Tulkens PM. Comparative stability studies of antipseudomonal β-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother. 2002;46:2327-32.
49. Baririan N, Chanteaux H, Viaene E, Servais H, Tulkens PM. Stability and compatibility study of cefepime in comparison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother. 2003;51:651-8.
50. Servais H, Tulkens P. Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients. Antimicrob Agents Chemother. 2001;45;2643-7.